NCT07095257 - Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 15, 2026

Conditions

Respiratory Viral Infection

Interventions

DRUG

ZX-7101A for oral suspension

ZX-7101A will be administered as oral suspension in a single dose on Day 1. Oseltamivir phosphate matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.

DRUG

Oseltamivir phosphate for oral suspension

Oseltamivir phosphate will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive ZX-7101A matching placebo as oral suspension, single dose on Day 1.